Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

SRx Health Solutions (SRXH) EBITDA Margin (2016 - 2025)

SRx Health Solutions (SRXH) has disclosed EBITDA Margin for 12 consecutive years, with 65.54% as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBITDA Margin fell 7910.0% year-over-year to 65.54%, compared with a TTM value of 25.42% through Jun 2025, down 810.0%, and an annual FY2024 reading of 32.73%, up 8761.0% over the prior year.
  • EBITDA Margin was 65.54% for Q2 2025 at SRx Health Solutions, down from 15.2% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 246.99% in Q4 2022 and bottomed at 223.13% in Q4 2023.
  • Average EBITDA Margin over 5 years is 20.65%, with a median of 27.45% recorded in 2021.
  • The sharpest move saw EBITDA Margin surged 29229bps in 2022, then plummeted -47012bps in 2023.
  • Year by year, EBITDA Margin stood at 45.3% in 2021, then surged by 645bps to 246.99% in 2022, then tumbled by -190bps to 223.13% in 2023, then skyrocketed by 121bps to 47.44% in 2024, then tumbled by -238bps to 65.54% in 2025.
  • Business Quant data shows EBITDA Margin for SRXH at 65.54% in Q2 2025, 15.2% in Q1 2025, and 47.44% in Q4 2024.